Published on : Oct 07, 2016
ALBANY, New York, Oct 07, 2016: The report is titled “PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2025,” and is available for sale on the company website. It provides a holistic overview of the global type 2 diabetes market and the various factors influencing its growth. Besides presenting insights into the growth drivers and restraints, the report also includes exhaustive information pertaining to the therapeutics for type 2 diabetes currently available in the market, and the ones that are in the pipeline.
The type 2 diabetes market has already reached its maturity and characterized by the presence of many inexpensive generics. Despite its late-stage pipeline being crowded with me-too drugs, the market is projected to witness strong growth between 2015 and 2025. The dramatic increase in the prevalence of type 2 diabetes and considerable efforts by physicians to delay disease progression are the key factors fuelling the global type 2 diabetes market.
According to analysts, the burden of diabetic complications can be reduced through the use of novel branded drugs and combination therapies. Due to such findings, the type 2 diabetes market is expected to witness a paradigm shift in the generally preferred class of drugs by physicians. Moreover, the increased adoption of drugs from the sodium-glucose co-transporter-2 inhibitor (SGLT-2I) class and glucagon-like peptide-1 receptor agonist (GLP-1RA) class is expected to occur. These segments are also expected to report the fastest growth at a CAGR of 13% and 12.2%, respectively during the forecast period.
Click here to get more info with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=816331
Although the market for type 2 diabetes has several well-established therapies, it is still marked by the presence of many unmet needs. The report identifies these needs and examines whether novel therapeutics will be able to fulfil the needs still prevalent in the global type 2 diabetes market. The report identifies the most lucrative regional markets for type 2 diabetes and analyzes the factors that will affect the markets trajectory across these regions.
Due to the high prevalence of diabetes in developed regions, they are expected to provide lucrative opportunities for the market’s growth. The rising sedentary lifestyle is also projected to contribute to the market’s expansion. Besides witnessing opportunities across developed economies, the market players are focusing on penetrating in emerging nations. The rising healthcare spending and the increasing willingness among consumers to pay for advanced medical treatments have been fuelling demand for advanced measures for diabetes treatment in developing countries.
The key players as well as the most prominent generic brands are profiled in the report. AstraZeneca, GlaxoSmithKline, Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Merck & Co., Sanofi, Johnson & Johnson, Novartis, Roche, and Pfizer are a few of the companies, the profiles of which are included in the report. Strategies adopted by these enterprises are studied in detail. The report also provides insights into the product portfolio and pipeline of these companies.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org